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Introduction {#sec1}
============

Conventional systemic and biologic therapies are highly effective in the treatment of moderate to severe psoriasis; however, treatment effectiveness is much lower in routine clinical practice than in clinical trials ([@bib10], [@bib18]). Patients need to adhere to their medication, yet approximately half of medications are not taken as prescribed ([@bib28]). There is a lack of high-quality data on levels of adherence to systemic therapies outside of clinical trials, and the factors influencing adherence are largely unknown ([@bib36]).

Non-adherence can be intentional, where patients make a deliberate decision not to follow the prescribed medication regimen, such as altering the dose, timing, or frequency of their systemic therapy. In other disease groups, patients' beliefs about their condition and medication are important drivers of non-adherence ([@bib13], [@bib20]). Patients' evaluations of personal need for medication for current and future health (necessity beliefs) and concerns about potential negative effects from treatment (concern beliefs) are important medication beliefs that influence intentional non-adherence, as posited by the extended Common-Sense Self-Regulatory Model of illness ([@bib19]) and treatment ([@bib14], [@bib15]).

Non-adherence can also be unintentional, such as forgetting to use the medication. The strength of the patient's routine, or habit, for taking their medication has been shown to influence unintentional non-adherence, especially when the patient has been using their treatment for an extended period of time ([@bib7], [@bib20], [@bib32], [@bib33]).

The aim of the Psoriasis Stratification to Optimise Relevant Therapy consortium is to better understand the determinants of treatment response to biologic therapies in psoriasis in order to develop a clinical algorithm to help stratify people to the most appropriate first-line biologic therapy and overcome trial-and-error prescribing ([@bib12]). In order to develop this stratified approach and optimize treatment effectiveness, it is necessary to examine non-adherence and understand its "modifiable" risk factors. The iMAP (Investigating Medication Adherence in Psoriasis) study is a large national multi-site study collecting biomedical and psychological data from patients prescribed systemic therapies at 35 dermatology centers in England. All patients are enrolled in the British Association of Dermatologists Biologic Interventions Register (BADBIR), a pharmacovigilance register representing a "real-world" cohort of psoriasis patients using systemic therapies ([@bib4], [@bib17]).

The objectives of this study were to: (i) assess real-world levels of intentional and unintentional non-adherence to conventional systemic and biologic therapies used for psoriasis; (ii) assess whether patients can be categorized into groups with similar medication beliefs and; (iii) examine whether psychological and biomedical factors are associated with non-adherence to systemic therapies. To identify the optimal number of medication belief groups, we used latent profile analysis (LPA), which categorizes individuals with similar profiles on a set of continuous variables (medication beliefs) into discrete groups or latent classes, represented by a categorical latent variable (medication belief group).

Results {#sec2}
=======

Demographic, clinical, and psychological data {#sec2.1}
---------------------------------------------

A total of 811 patients using a systemic therapy for the treatment of psoriasis were included in the study ([Table 1](#tbl1){ref-type="table"}). In the biologic cohort (64.7%, n = 525), the most common prescribed biologic was adalimumab (52.5%; n = 258), followed by ustekinumab (32.6%; n = 160) and etanercept (14.9%; n = 73). In total, 75.4% (n = 352) were prescribed their first biologic therapy (biologic naïve) and 7% (n = 36) were using a concomitant systemic therapy. In the conventional systemic cohort (35.3%; n = 286), methotrexate was the most common (52%; n = 141), followed by cyclosporine (21.8%; n = 59), acitretin (19.2%; n = 52), and fumaric acid esters (7%; n = 19).Table 1Demographic, clinical, and psychological data at baseline (n = 811)CharacteristicsTotal Sample (n = 811)Conventional Cohort[1](#tbl1fn1){ref-type="table-fn"} (35.3%, n = 286)Biologic Cohort[2](#tbl1fn2){ref-type="table-fn"} (64.7%, n = 525)*P-*Value[3](#tbl1fn3){ref-type="table-fn"}DemographicAge, y, mean ± SD48.1 ± 13.148.4 ± 13.747.9 ± 12.80.599 n720254466Male, % (n)57.1 (411)49.2 (125)61.4 (286)**0.002** n720254466Disease Age of onset, y, mean ± SD25.4 ± 15.127.8 ± 16.824.1 ± 13.9**0.001** n716252464 Disease duration, y, mean ± SD23.3 ± 13.821.3 ± 14.824.3 ± 13.0**0.004** n718253465 PASI at the start of treatment, mean ± SD14.3 ± 7.014.8 ± 7.514.0 ± 6.70.164 n693245448 DLQI at the start of treatment, mean ± SD13.7 ± 7.915.6 ± 6.312.6 ± 8.5**≤0.001** n684244440Comorbidities Presence of ≥1 comorbidity,[4](#tbl1fn4){ref-type="table-fn"} % (n)65.2 (471)62 (158)67 (313)0.172 n722255467 Inflammatory arthritis, % (n)17.3 (124)9.5 (24)21.5 (100)**≤0.001** n718253465Treatment Treatment duration, mo, mean ± SD11.4 ± 13.57.0 ± 11.113.9 ± 14.1**≤0.001** n744265479Psychological distress (HADS[5](#tbl1fn5){ref-type="table-fn"}) Anxiety, mean ± SD6.7 ± 4.36.9 ± 4.46.5 ± 4.30.168 n794281513 Depression, mean ± SD4.8 ± 4.05.3 ± 4.24.5 ± 3.9**0.010** n796280516Illness beliefs and emotional response toward psoriasis (IPQ-R[6](#tbl1fn6){ref-type="table-fn"}) Illness identity[7](#tbl1fn7){ref-type="table-fn"} (symptoms), mean ± SD4.2 ± 2.84.1 ± 2.64.3 ± 2.90.420 n784275509 Timeline acute/chronic, mean ± SD4.2 ± 0.64.2 ± 0.64.3 ± 0.6**0.020** n796279517 Timeline cyclical, mean ± SD3.3 ± 0.73.3 ± 0.73.2 ± 0.70.080 n803284519 Consequences, mean ± SD3.7 ± 0.73.6 ± 0.73.7 ± 0.70.113 n804286518 Personal controllability, mean ± SD3.0 ± 0.73.0 ± 0.73.0 ± 0.80.365 n800281519 Treatment controllability, mean ± SD3.7 ± 0.63.6 ± 0.53.8 ± 0.6**≤0.001** n792282510 Coherence (understanding), mean ± SD3.4 ± 0.93.2 ± 0.93.5 ± 0.9**≤0.001** n800281519 Emotional response, mean ± SD3.4 ± 0.83.5 ± 0.83.4 ± 0.90.702 n802284518Medication beliefs (BMQ[6](#tbl1fn6){ref-type="table-fn"}) Specific necessity, mean ± SD3.7 ± 0.83.5 ± 0.83.9 ± 0.8**≤0.001** n795281514 Specific concerns, mean ± SD2.5 ± 0.72.7 ± 0.72.3 ± 0.6**≤0.001** n794280514 General overuse, mean ± SD2.7 ± 0.72.7 ± 0.72.7 ± 0.70.287 n804286518 General harmfulness, mean ± SD2.3 ± 0.62.3 ± 0.62.2 ± 0.6**0.029** n802286516[^1][^2][^3][^4][^5][^6][^7][^8]

Patients in the biologic cohort were significantly more likely to be male; have younger age of onset of psoriasis; longer duration of disease; more likely to have a diagnosis of inflammatory arthritis; report lower Dermatology Life Quality Index scores at the start of their systemic therapy; have longer duration of systemic therapy; hold stronger beliefs in the chronicity of their psoriasis; stronger beliefs that their systemic therapy is necessary and helps to control and manage their symptoms; weaker concerns about their systemic therapy and medicines in general; greater perceived understanding of psoriasis and its causes and triggers (coherence); and report fewer symptoms of depression compared to those in the conventional cohort.

Non-adherence to systemic therapies and medication-taking habit/routine strength {#sec2.2}
--------------------------------------------------------------------------------

Only 7.3% (n *=* 11) of patients using ustekinumab were classified as overall non-adherent. Ustekinumab is predominately nurse-administered in the United Kingdom and this value may reflect the contrast between regular patient self-administered and 12-weekly nurse-administered injection in most centers.

[Table 2](#tbl2){ref-type="table"} presents the proportion of patients classified as non-adherent to self-administered systemic therapies; those on ustekinumab (n = 160) and those with missing biologic treatment type (n = 34) were excluded. A significant proportion of patients using self-administered oral conventional systemic or subcutaneous biologic therapies (etanercept, adalimumab) were classified as non-adherent (22.4%; n = 134); 12% (n = 72) were classified as intentionally and 10.9% (n = 66) were classified as unintentionally non-adherent ([Table 2](#tbl2){ref-type="table"}). A higher proportion of patients prescribed an oral conventional systemic were classified as non-adherent compared to those prescribed etanercept or adalimumab (29.2% \[n = 82\] vs. 16.4% \[n = 52\]; p ≤ 0.001). [Figure 1](#fig1){ref-type="fig"} presents the proportion of patients classified as overall non-adherent within the oral conventional systemic and self-administered biologic cohorts. Fumaric acid esters were excluded from [Figure 1](#fig1){ref-type="fig"} due to small sample size (7%; n = 19). As shown in [Figure 1](#fig1){ref-type="fig"}, a higher proportion of patients prescribed etanercept were classified as non-adherent compared with adalimumab. A higher proportion of patients prescribed cyclosporine were classified as non-adherent compared with acitretin or methotrexate.Figure 1**Proportion of patients classified as overall non-adherent within the oral conventional systemic and self-administered biologic cohorts.** Fumaric acid esters were excluded due to small sample size (7%, n = 19).Table 2Proportion of patients classified as non-adherent to self-administered systemic therapies (n = 617)AdherenceTotal SampleConventional Cohort[1](#tbl2fn1){ref-type="table-fn"}Biologic Cohort[2](#tbl2fn2){ref-type="table-fn"}*P-*value[3](#tbl2fn3){ref-type="table-fn"}Overall non-adherent, % (n)22.4 (134)29.2 (82)16.4 (52)**≤0.001** n599281318Intentionally non-adherent, % (n)12 (72)15.3 (43)9.1 (29)**0.020** n599281318Unintentionally non-adherent, % (n)10.9 (66)14.5 (41)7.7 (25)**0.007** n605282323[^9][^10][^11]

Using the Self-Report Habit Index ([@bib40]), patients using a self-administered systemic therapy reported strong routine, or habit, for taking their systemic therapy, with a mean ± standard deviation score of 41.5 ± 9.7 out of a possible score of 60. A high proportion of the sample agreed or strongly agreed that taking their systemic therapy is something they do "frequently" (91.2%, n = 542), "automatically" (85.2%, n = 509), and "as part of their routine" (83.7%, n = 498).

Medication belief groups {#sec2.3}
------------------------

The optimal number of medication belief groups was identified using LPA. The model fit statistics for 1- to 5-class solutions indicated a 3-class solution was optimal ([Supplementary Table S1](#appsec1){ref-type="sec"} online); patients can be classified into three groups characterized by distinct medication beliefs. Sample means (95% confidence intervals \[CIs\]) of medication beliefs for the 3-class solution are presented in [Figure 2](#fig2){ref-type="fig"}.Figure 2**Sample means (95% confidence intervals) of medication beliefs for the three-class solution.**

Each of the three medication belief groups perceived a strong need for their systemic therapy (specific necessity) and believed that their therapy was effective in managing their psoriasis symptoms (treatment controllability), but differed in their level of medication concerns.

Group 1 (26.4%; n = 213) was labeled "strongly concerned." Patients in this group reported the strongest concerns about their systemic therapy, these included potential long-term adverse effects and future medication dependency. Patients believed they lacked understanding about their systemic therapy. Those in Group 1 also reported the strongest concerns about the overuse of medicines in general: patients believed that doctors use too many, and place too much trust on medicines, and that doctors would prescribe fewer medicines if they had more time with patients. Patients also reported the strongest concerns about the harmfulness of medicines in general, including strong beliefs that people who take medicines should stop their treatment for a while every now and again, that most medicines "are addictive," "are poisons," and "do more harm than good."

Group 2 (61%, n = 493) was labeled "side effects and overuse." Although patients reported weaker medication concerns than Group 1, they still expressed strong concerns about potential long-term adverse effects from their systemic therapy and concerns about the general overuse of medicines. Group 3 (12.6%, n = 102) was labeled "treatment resolved"; patients reported far lower ratings for medication concerns compared to Group 1 and 2.

The proportion of patients classified into the three medication belief groups significantly differed by treatment cohort (*P* ≤ 0.001), with a higher proportion of patients in the biologic cohort classified into Group 3 (15.5%; n = 81) compared with the conventional cohort (7.3%; n = 21).

Factors associated with non-adherence to self-administered systemic therapies {#sec2.4}
-----------------------------------------------------------------------------

Factors influencing non-adherence may be different for ustekinumab (e.g., delay in administration) compared with self-administered systemic therapies. We did not have data on these "system" factors and for these reasons patients prescribed ustekinumab (n = 160) and those with missing biologic treatment type (n = 34) were excluded from the analyses examining factors associated with adherence. The results from the regression analyses are presented in [Table 3](#tbl3){ref-type="table"}.Table 3The univariable and multivariable regression models for non-adherence to self-administered systemic therapies[1](#tbl3fn1){ref-type="table-fn"}VariableOverall Non-AdherentIntentionally Non-AdherentUnintentionally Non-AdherentUnivariableMultivariableUnivariableMultivariableUnivariableMultivariableDemographic Age, y**0.97 (0.96−0.99)0.97 (0.95−0.99)**1.00 (0.98−1.02)1.00 (0.97−1.03)**0.95 (0.93−0.97)0.95 (0.92−0.98)** n553449553449559451 Male1.32 (0.87−2.0)1.67 (0.97−2.89)1.11 (0.66−1.88)1.39 (0.71−2.72)1.03 (0.60−1.76)1.26 (0.63−2.53) n553449553449559451Disease Disease duration, y**0.98 (0.97−1.00)**1.01 (0.98- 1.03)1.00 (0.98−1.02)1.01 (0.99−1.04)0.98 (0.96−1.00)1.00 (0.97−1.03) n551449551449557451 PASI at the start of treatment0.98 (0.95−1.01)0.97 (0.94−1.01)0.98 (0.94−1.02)0.96 (0.91−1.01)1.01 (0.97−1.05)1.00 (0.95−1.04) n531449531449537451 DLQI at the start of treatment1.01 (0.99−1.04)1.01 (0.98−1.05)1.02 (0.99−1.06)1.03 (0.98−1.08)1.01 (0.97−1.05)0.99 (0.95−1.04) n525449525449530451Comorbidities Presence of ≥1 comorbidity[2](#tbl3fn2){ref-type="table-fn"}0.92 (0.61−1.41)1.35 (0.75−2.41)0.87 (0.51−1.49)0.95 (0.46−1.96)0.98 (0.56−1.72)1.65 (0.78−3.49) n554449554449560451 Inflammatory arthritis0.91 (0.53−1.55)1.35 (0.66−2.76)1.21 (0.63−2.32)1.78 (0.74−4.24)1.03 (0.52−2.07)1.60 (0.64−4.02) n551449551449557451Treatment Treatment duration, mo1.01 (1.00−1.03)**1.04 (1.02−1.06)**1.02 (1.00 - 1.03)**1.04 (1.01−1.06)**1.00 (0.99−1.02)**1.03 (1.01−1.06)** n573449573449579451 Conventional therapy**2.11 (1.42−3.12)4.34 (2.38−7.91)1.80 (1.09−2.97)3.21 (1.54−6.67)2.03 (1.20−3.43)4.87 (2.24−10.59)** n599449599449605451Psychological distress (HADS) Anxiety1.03 (0.98−1.07)1.04 (0.95−1.13)1.02 (0.97−1.08)1.04 (0.93−1.16)1.05 (0.99−1.11)1.01 (0.91−1.13) n588449588449594451 Depression1.01 (0.96−1.06)0.95 (0.86−1.04)1.00 (0.94−1.06)0.93 (0.82−1.04)1.04 (0.98−1.10)0.99 (0.88−1.12) n588449588449594451Illness beliefs and emotional response toward psoriasis (IPQ-R) Illness identity (symptoms)1.04 (0.97−1.11)0.99 (0.90−1.09)1.071 (0.99−1.17)1.06 (0.95−1.19)0.98 (0.89−1.08)0.88 (0.77−1.01) n579449579449585451 Timeline acute/chronic0.99 (0.72−1.36)1.04 (0.62−1.72)0.86 (0.57−1.28)0.98 (0.52−1.85)**1.86 (1.13−3.06)2.16 (1.03−4.52)** n589449589449595451 Timeline cyclical1.19 (0.90−1.57)0.94 (0.63−1.39)1.28 (0.90−1.83)0.97 (0.60−1.59)1.06 (0.74−1.53)0.80 (0.48−1.31) n594449594449600451 Consequences0.99 (0.76−1.29)0.87 (0.50−1.52)1.01 (0.72−1.43)0.71 (0.35−1.45)**1.46 (1.00−2.11)**1.15 (0.58−2.30) n596449596449602451 Personal controllability**1.36 (1.04**−**1.77)**1.40 (0.95−2.07)1.07 (0.76−1.50)1.12 (0.69−1.81)1.38 (0.97−1.98)1.5 (0.92−2.45) n591449591449597451 Coherence (understanding)0.83 (0.68−1.01)0.88 (0.65−1.19)**0.72 (0.56−0.94)**0.85 (0.59−1.23)0.92 (0.70−1.20)0.78 (0.53−1.14) n591449591449597451 Emotional response towards psoriasis1.03 (0.82−1.31)1.18 (0.72−1.92)1.19 (0.88−1.61)1.52 (0.80−2.87)1.12 (0.82−1.54)0.95 (0.52−1.73) n595449595449601451Medication beliefs Group 1 (strongly concerned)[3](#tbl3fn3){ref-type="table-fn"}**1.69 (1.12−2.56)1.92 (1.09−3.39)2.35 (1.41−3.90)2.27 (1.16−4.47)**1.14 (0.64−2.0)1.00 (0.46−2.16) n597449597449603451Strength of the patient's habit, or routine, for using their prescribed systemic therapy Habit**0.94 (0.92−0.97)0.94 (0.91−0.97)0.96 (0.93−0.98)0.95 (0.92−0.98)0.93 (0.90−0.95)0.92 (0.89−0.96)** n570449570449573451[^12][^13][^14][^15]

### Overall non-adherence {#sec2.4.1}

The multivariable model showed that being on a conventional systemic (odds ratio \[OR\] = 4.34, 95% CI = 2.38−7.91), having strong medication concerns (OR = 1.92; 95% CI = 1.09−3.39), weaker routine/habit for taking their systemic therapy (OR = 0.94; 95% CI = 0.91−0.97), longer treatment duration (OR = 1.04; 95% CI = 1.02−1.06), and younger age (OR = 0.97, 95% CI = 0.95−0.99) were factors associated with being classified as overall non-adherent. Together, these variables were significantly associated with overall non-adherence (χ^2^ \[20\] = 73.32, *P* ≤ 0.001) and accounted for 23.4% of the variability in the overall non-adherent variable.

### Intentional non-adherence {#sec2.4.2}

Being on a conventional systemic therapy (OR = 3.21, 95% CI = 1.54−6.67), having strong medication concerns (OR = 2.27, 95% CI = 1.16−4.47), weaker routine/habit for taking their systemic therapy (OR = 0.95; 95% CI = 0.92−0.98), and longer treatment duration (OR = 1.04, 95% CI = 1.01−1.06) were also factors associated with intentional non-adherence. The model was significant (χ^2^ \[20\] = 40.91, *P* = 0.004) and accounted for 17.0% of the variability in the intentionally non-adherent variable.

### Unintentional non-adherence {#sec2.4.3}

Being on a conventional systemic therapy (OR = 4.87, 95% CI = 2.24−10.59), stronger perceptions of psoriasis being a chronic condition (OR = 2.16, 95% CI = 1.03−4.52), weaker routine/habit for taking their systemic therapy (OR = 0.92, 95% CI = 0.89−0.96), younger age (OR = 0.95, 95% CI 0.92−0.98), and longer treatment duration (OR = 1.03, 95% CI = 1.01−1.06) were factors associated with unintentional non-adherence. The model was significant (χ^2^ \[20\] = 65.92, *P* = ≤ 0.001) and accounted for 26.6% of the variability in the unintentional non-adherent variable.

Discussion {#sec3}
==========

Main findings {#sec3.1}
-------------

This is the largest study to assess adherence to conventional systemic and biologic therapies used for psoriasis in a real-world setting to date; 22.4% of patients using self-administered systemic therapies are classified as non-adherent, with a higher proportion of patients using a conventional systemic classified as non-adherent (29.2%) compared to those using etanercept or adalimumab (16.4%). Patients' medication beliefs are key drivers of intentional non-adherence. Medication-taking routine or habit strength influences intentional and unintentional non-adherence.

Comparison to other studies {#sec3.2}
---------------------------

Adherence is known to be problematic across many long-term conditions ([@bib28]), with a recent study in rheumatoid arthritis showing that 27% of patients self-report non-adherence at least once within 6 months of starting a biologic therapy ([@bib2]). Both higher and lower levels of adherence to systemic therapies used for psoriasis have been reported in other studies reflecting differences in study inclusion criteria and size, and the use of non-validated self-report tools to assess adherence ([@bib36]). Previous adherence research has focused predominantly on demographic and clinical predictors, however, these variables show weak or inconsistent relationships with adherence in psoriasis ([@bib36]) and in other long-term conditions ([@bib8]), a finding consistent with our results. These factors are not readily amenable to change and have limited utility for informing adherence interventions. We have demonstrated that different "modifiable" factors are associated with intentional and unintentional non-adherence.

In other disease groups, the important influences of patients' medication beliefs on adherence have been demonstrated ([@bib13]). We have shown that a significant proportion of patients express conflicting beliefs about their systemic therapy; strong beliefs in the perceived need and effectiveness of their systemic therapy and strong concerns about its usage. Patients were more likely to make the decision to use their systemic therapies in ways that have not been prescribed, such as using less of it or stopping treatment for a while (intentional non-adherence) if they had unresolved medication concerns. Patient understanding of the causes and triggers of psoriasis and its disease mechanisms can be low ([@bib23]) and the current study suggests that this lack of "illness coherence" may contribute to intentional non-adherence. Patients' understanding of psoriasis will influence their beliefs about systemic therapies ([@bib15], [@bib25]), which is likely to account for the fact that it was not associated with intentional non-adherence after controlling for other variables.

Some instances of intentional non-adherence may be influenced by good disease control; patients may decide to strategically alter their treatment regimen if their symptoms have improved. The impact of disease control on medication non-adherence is likely to be mediated by patients' beliefs about their psoriasis and medication. Patients who perceive good disease control may report reduced perceived need for their treatment and decide to alter their treatment regimen, especially if they also report concerns about its usage. Psychological distress was not associated with non-adherence. Although depression is a known risk factor for non-adherence in long-term conditions ([@bib11]), we have previously shown that distress can remain high in psoriasis even if the patient is adhering to their treatment ([@bib37]).

In other disease groups, the strength of the patient's routine, or habit, for taking their medication has been shown to predict unintentional non-adherence, such as forgetting to use medication ([@bib3], [@bib32]). Habit-based interventions have been shown to be effective in improving medication adherence ([@bib6]). This study found habit strength was associated with intentional and unintentional non-adherence. Although medication beliefs were not associated with unintentional non-adherence, stronger perceptions of psoriasis as a chronic condition with serious consequences were significant contributors. Future work should explore whether unresolved patient concerns about psoriasis and medication are a barrier to developing good medication-taking routines.

In the United Kingdom, patients generally use topical therapies before commencing a conventional therapy ([@bib26]). Many patients express concerns about topical therapies and perceive or experience poor health care support ([@bib23], [@bib24], [@bib37]). Beliefs based on their earlier experiences can persist ([@bib35]) and may influence patients' behavior or lower expectations about subsequent use of conventional therapies. Fewer patients in the conventional cohort were classified as having positive medication beliefs compared with those using a biologic. Differences in beliefs rather than mode of administration may account for the difference in non-adherence between the conventional and biologic cohorts. The vast majority of patients prescribed ustekinumab were classified as adherent, consistent with its high drug survival ([@bib41]). Ustekinumab is predominately nurse-administered in the United Kingdom; although this will help support adherence patients may still hold unresolved medication concerns or worries about their therapy.

Implications for clinicians {#sec3.3}
---------------------------

Clinicians need to be aware of the possibility of non-adherence. More than 20% of patients in this study expressed strong beliefs in the personal need for treatment while simultaneously reporting strong concerns about their use of psoriasis-specific treatments, as well about use of medicines in general. Intentional non-adherence was most common in this group. This group may benefit most from interventions targeting key medication beliefs ([@bib31], [@bib34]). The UK [@bib27] Medicines Adherence Guidelines provides recommendations for supporting shared medication decision-making and adherence. Clinicians should talk with the patient to understand their perspective and establish key medication beliefs before prescribing new treatments and when reviewing medicines. This can be achieved by using standardized assessment tools, such as the Beliefs about Medicines Questionnaire ([@bib16]) or by asking the patient what they know, believe, and understand about their medicines, including any specific concerns they may have about their medication. Doing so will provide an opportunity for the clinician to modify incorrect or incomplete beliefs and help support patient treatment decision-making. Unintentional non-adherence needs an interventional approach that focuses on developing planned and automatic routines for medication-taking ([@bib6], [@bib29]). Encouraging the patient to discuss how medication usage fits into their daily life and any practical barriers they may face will help to identify potential solutions and develop good medication-taking habits and routines.

Strengths and limitations of the study {#sec3.4}
--------------------------------------

The real-world cohort study design ensures that patients are representative of those receiving treatment in routine clinical practice. However, an inherent limitation to an observational study is the potential for selection bias. Although the overall sample size was large, 10.5% of patients were not matched to BADBIR and were excluded from the regression models. Adherence rates for the separate systemic therapies should be interpreted with some caution due to smaller number of patients in these specific treatment groups and thus, we were unable to explore why adherence varied by specific treatment type. Ustekinumab is predominately nurse-administered in the United Kingdom, however it is possible that some patients were self-administering. Although it is not possible to infer causality from cross-sectional analyses, the use of appropriate theoretical frameworks and validated data collection tools are major strengths. Although medication belief Groups 2 and 3 had different belief profiles, they were combined in adherence analyses due to the small number of cases in Group 3 being classified as non-adherent.

Self-report tools of adherence can be criticized for being influenced by poor patient recall or reporting bias and so they can overestimate adherence. However, they are the only tools able to distinguish intentional and unintentional non-adherence. The validated Medication Adherence Report Scale has been shown to provide a good estimate of adherence in other conditions ([@bib15], [@bib30]). When we use self-report measures of adherence, it is important that we distinguish non-adherence, where the patient themselves decide to use their treatment in ways that have not been prescribed, from clinician-prescribed cessation of treatment, where the clinician may appropriately stop treatment, for example, due to an infection. We appropriately modified the Medication Adherence Report Scale so the items referred to patient treatment decision-making. If this confounder were present, we would not expect a relationship between beliefs and medication-taking habit/routine with non-adherence. Given that we found this association, we are confident that we measured true non-adherence, rather than appropriate clinician-prescribed variation in treatment usage.

Summary {#sec3.5}
-------

Significant proportions of patients with psoriasis prescribed self-administered systemic therapies report intentional and unintentional non-adherence with their treatment regimen. After accounting for relevant variables, patients' medication beliefs were associated with intentional non-adherence, with the strength of the patients' medication-taking routine associated with unintentional non-adherence. This study emphasizes the need to assess adherence when determining factors influencing treatment response.

Materials and Methods {#sec4}
=====================

Patients attending 35 dermatology clinics across England were recruited into the iMAP study between March 2013 and September 2016. Patients with a diagnosis of psoriasis under the care of a dermatologist, prescribed an oral conventional systemic (methotrexate, cyclosporine, acitretin, fumaric acid esters), and/or a subcutaneous biologic treatment (etanercept, adalimumab, ustekinumab), aged ≥18 years, and enrolled on BADBIR were eligible for inclusion into the study. In total, 811 psoriasis patients were included in the analysis ([Supplementary Figure S1](#appsec1){ref-type="sec"} online).

Measures {#sec4.1}
--------

Psoriasis patients were instructed to complete a questionnaire independently and anonymously and return to the investigator. It contained the following measures:1.The Medication Adherence Report Scale ([@bib15]) that assesses the frequency of intentional (6-items) and unintentional (2-items) non-adherent behaviors on a 5-point Likert scale ranging from very often (= 1) to never (= 5), with higher scores indicating higher levels of adherent behavior. It has been modified and used extensively across many disease groups ([@bib15], [@bib30]). All intentional items were modified to begin with the stem "I decided" (e.g., "I decided to alter the dose of my psoriasis injection/tablets"). Patients were classified into overall adherent/non-adherent categories using a score of ≤38/40, and also classified into intentional (≤28/30) and unintentional (≤8/10) categories ([@bib5], [@bib39]).2.The strength of the patient's habit, or routine, for using their prescribed systemic therapy was assessed using the validated Self-Report Habit Index ([@bib40]). Each item is scored on a 5-point Likert scale (strongly disagree \[= 1\] to strongly agree \[= 5\]) and summed, with scores ranging from 12 to 60, with higher scores indicating stronger habit.3.Patients' beliefs about their psoriasis and emotional responses toward their condition were assessed using the validated Revised Illness Perceptions Questionnaire ([@bib21]). Seven subscales (39 items) measure perceptions of: how long psoriasis will last (timeline acute/chronic/cyclical); consequences associated with the condition (consequences); personal control; treatment control; understanding of their condition (coherence); and emotional response towards psoriasis. Each item was scored on a 5-point Likert scale (strongly disagree \[= 1\] to strongly agree \[= 5\]). A mean score was calculated for each subscale, ranging from 1 to 5, with higher scores indicating stronger illness beliefs and more negative emotional response towards psoriasis. Symptoms attributed to psoriasis ("illness identity") were assessed (17 items), with each yes-rated symptom scored and summed (yes \[= 1\], no \[= 0\]), ranging from 0 to 17. In line with the previous research ([@bib9]), one psoriasis-specific item was included in the timeline cyclical subscale ("If my psoriasis clears it will always come back") and three additional symptoms were included in the identity scale ("skin flaking," "burning sensations," and "itching").4.The Beliefs about Medicines Questionnaire ([@bib16]) assesses: patients' perceived need for their prescribed systemic therapy (6-items specific-necessity); concerns about the potential adverse consequences of taking it (five items specific-concerns); beliefs in the general harmfulness of medication (four items General-Harm) and; beliefs that medications are overused by doctors (four items General-Overuse). The Beliefs about Medicines Questionnaire was appropriately adapted for use in psoriasis ([@bib38]). Each item is scored on a 5-point scale ("strongly disagree" \[= 1\] to "strongly agree" \[= 5\]), with higher scores indicating stronger medication beliefs. A mean score was calculated for each subscale, with scores ranging from 1 to 5.5.The Hospital Anxiety and Depression Scale ([@bib42]) provides an assessment of symptoms of anxiety (seven items) and depression (seven items) among patients with a physical illness. Patients indicate the strength of agreement with each item on a 0- to 3-point scale. Items are summed to create a Hospital Anxiety and Depression Scale anxiety and depression score, both ranging from 0 to 21. A score of ≥8 indicates a possible or probable caseness of anxiety or depression ([@bib1]). Permission was granted to use the Hospital Anxiety and Depression Scale.

Once patients were recruited into the iMAP study, their corresponding data from BADBIR were accessed (with written informed patient consent). Demographic (age, sex) and disease data (age of onset, disease duration, comorbidities) recorded at BADBIR registration were extracted. Treatment variables (treatment type and duration) were extracted at times corresponding to the dates when patients completed the iMAP questionnaire. Psoriasis Area and Severity Index and Dermatology Life Quality Index scores were extracted at the time the patient started the therapy; the closest Psoriasis Area and Severity Index and Dermatology Life Quality Index scores recorded within 6 months of the treatment start date (before or after) were extracted.

Data analysis {#sec4.2}
-------------

Differences in baseline characteristics between the conventional and biologic cohorts were analyzed using *t*-tests and χ^2^ tests ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). LPA was used to identify the optimal number of medication belief groups. The Beliefs about Medicines Questionnaire subscales of specific necessity, specific concerns, general overuse, and general harmfulness, and the Revised Illness Perception Questionnaire subscale of treatment control, were included in the LPA analysis. Three participants had missing data for all five variables and were excluded from the analysis. The model fit statistics for LPA models with one through five class solutions were examined ([Supplementary Table S1](#appsec1){ref-type="sec"}). These were the Bayesian Information Criterion, where smaller values indicate a better fit, and the Vuong-Lo-Mendell-Rubin Likelihood ratio test and the Lo-Mendell-Rubin Adjusted Likelihood ratio test, both of which compare the current model to a model with one less latent class. Entropy provides a measure of the classification quality of the model, with values approaching 1 indicating a good separation of classes.

Three separate logistic multiple regressions were conducted ([Table 3](#tbl3){ref-type="table"}). The odds ratios represent the effect of a 1-unit change in the predictor; they are not standardized and their size depends largely on the units used for the predictor variables. Medication belief Groups 2 and 3 were combined, due to the small number of cases in Group 3 classified as non-adherent (≤8 cases). LPA was conducted in M*plus* 7 ([@bib22]) and all other analyses were conducted in SPSS, version 23 (IBM, Armonk, NY).

Rates of missing data were very low for the Medication Adherence Report Scale, Self-Report Habit Index, Beliefs about Medicines Questionnaire, Revised Illness Perception Questionnaire and Hospital Anxiety and Depression Scale, ranging from 0.9% to 5.3%. A small number of patients were unable to be matched with data drawn from the registry ([Supplementary Figure S1](#appsec1){ref-type="sec"}), the amount of missing data was higher for variables obtained from BADBIR, ranging from 6% to 15.7%.

Ethical approval {#sec4.3}
----------------

Ethical approval for iMAP was obtained from NHS Research Ethics Committee North West England (reference 12/NW/0619) in December 2012 (and from research ethics committees local to each recruiting site). All subjects gave written informed patient consent prior to data collection.
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[^1]: Abbreviations: BMQ, Beliefs about Medicines Questionnaire; DLQI, Dermatology Life Quality Index; HADS, Hospital Anxiety and Depression Scale; IPQ-R, Revised Illness Perception Questionnaire; PASI, Psoriasis Area and Severity Index; SD, standard deviation.

[^2]: Includes methotrexate, cyclosporine, acitretin, and fumaric acid esters.

[^3]: Includes adalimumab, ustekinumab, and etanercept.

[^4]: The *P*-value tests for significant differences between the conventional systemic and biologic cohorts using *t*-tests and χ^2^ tests. Boldface indicates *P* \< 0.05.

[^5]: Includes any of (excluding psoriatic arthritis) hypertension, angina, ischemic heart disease, stroke, epilepsy, asthma, chronic obstructive pulmonary disease, peptic ulcer, renal disease, hepatic disease, tuberculosis, demyelinating disease, diabetes, impaired glucose tolerance, depression, non-skin cancer, immunodeficiency syndrome, thyroid disease, other.

[^6]: The possible score range for HADS anxiety and HADS depression is 0−21.

[^7]: The possible score range for all IPQ-R and BMQ items (excluding illness identity) is 1−5.

[^8]: The possible score range for illness identity is 0−17.

[^9]: Includes methotrexate, cyclosporine, acitretin and fumaric acid esters.

[^10]: Includes adalimumab and etanercept.

[^11]: *P*-value tests for significant differences between the conventional systemic and biologic cohorts using χ^2^ tests. Boldface indicates *P* ≤ 0.05.

[^12]: Abbreviations: CI, confidence interval; HADS, hospital anxiety and depression scale; IPQ-R, Illness Perception Questionnaire- Revised; OR, odds ratio.

[^13]: Self-administered systemic therapies include methotrexate, cyclosporine, acitretin, fumaric acid esters, adalimumab, and etanercept. Boldface indicates *P* ≤ 0.05.

[^14]: Reference category: no comorbidities (excluding psoriatic arthritis); includes any of hypertension, angina, ischemic heart disease, stroke, epilepsy, asthma, chronic obstructive pulmonary disease, peptic ulcer, renal disease, hepatic disease, tuberculosis, demyelinating disease, diabetes, impaired glucose tolerance, depression, non-skin cancer, immunodeficiency syndrome, thyroid disease, other.

[^15]: Reference category: Medication belief Group 2 (side effects and overuse) and Group 3 (treatment resolved).
